Morgan Stanley notes that a U.S. district court ruling on biosimilar Eylea infringement/validity was issued in Regeneron’s favor and views this as an incremental positive for shares given that a potential delay in biosimilar Eylea entry could give the company more time to convert the market from low dose to high dose Eylea. The firm keeps an Overweight rating and $941 price target on Regeneron shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron (NASDAQ:REGN) Gains after Patent Suit Mostly Wins
- Regeneron VP Fenimore sells $1.6M in company shares
- Regeneron price target raised to $1,125 from $1,050 at Oppenheimer
- Regeneron’s treatment of Hemophilia B granted FDA orphan designation
- Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
